BlogFile: Targacept, Inc. (TRGT)
BioHealth Investor.com
COMPANY BlogFILE
updated: May 13, 2007
TARGACEPT, Inc.
200 East First Street, Suite 300
Winston-Salem, NC 27101-4165
USA
Phone: (336) 480-2100
Fax: (336) 480-2107
www.targacept.com
Investor/Public Relations
Alan Musso
Vice President and Chief Financial Officer
(336) 480-2186
(336) 480-2103
alan.musso@targacept.com
COMPANY DESCRIPTION
Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs.NNrs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.
BUSINESS INFORMATION
Public company
Ticker: TRGT
Market: NASDAQ
Industry: Biotechnology
LATEST BLOG COMMENTARY
Tiny Targacept Experiences Unusual Volume Surge
SeekingAlpha
April 18, 2007
Targacept: Late Day Volume Surge Deserves Attention
BioHealth Investor
April 17, 2007
Wednesday Pre-market Notes By Stock Ticker
SeekingAlpha
April 12, 2007
Barron’s Alzheimer’s Article Only Scratches the Surface
24/7 Wall St.
March 31, 2007
Friday’s Top Biotech and Medical Stocks
BioHealth Investor
November 04, 2007
Thursday’s Top Biotech and Medical Stocks
BioHealth Investor
November 02, 2006
Source: BioHealth Investor.com
___________________
BlogFile: Dendreon Corporation (DNDN)
BioHealth Investor.com
COMPANY BlogFILE
updated: May 15, 2007
DENDREON CORPORATION
3005 First Avenue
Seattle, WA 98121
Phone: (206) 256-4545
Fax: (206) 256-0571
www.dendreon.com
Investor/Public Relations
(206) 829-1500
ir@dendreon.com
COMPANY DESCRIPTION
Dendreon Corporation is a Seattle-based biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Through innovative science and technology, is striving to develop and commercialize products that address unmet medical needs, improve survival and have a favorable safety profile.
BUSINESS INFORMATION
Public company
Ticker: DNDN
Market: NASDAQ
Industry: Biotechnology
LATEST BLOG COMMENTARY
Dendreon, the Day That Could Have Been and What to Expect Now
24/7 Wall St.
May 15, 2007
Why Did the FDA Decide to Flunk Dendreon’s Provenge?
SeekingAlpha
May 14, 2007
Dendreon - Is Provenge Snake Oil or Cure?
The Disciplined Investor
May 12, 2007
DNDN… is it Over?
Echo To All
May 12, 2007
Rantasorous Rx
Health Business Blog
May 11, 2007
Comments From Dendreon’s Conference Call (May 10, 2007)
24/7 Wall St.
May 10, 2007
Dendreon Gets Complete Response Letter
Eye On FDA
May 09, 2007
Dendreon Nailed by FDA
24/7 Wall St.
May 09, 2007
Dendreon: The Short Story
SeekingAlpha
May 09, 2007
Dendreon: The Next Genentech/Amgen?
SeekingAlpha
May 04, 2007
Source: BioHealth Investor.com
____________________